Harvest Portfolios Group Inc. Buys 31,300 Shares of Sanofi (NASDAQ:SNY)

Harvest Portfolios Group Inc. lifted its stake in Sanofi (NASDAQ:SNY) by 298.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,800 shares of the company’s stock after purchasing an additional 31,300 shares during the period. Harvest Portfolios Group Inc.’s holdings in Sanofi were worth $2,275,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. B. Riley Wealth Advisors Inc. grew its holdings in Sanofi by 10.9% during the 1st quarter. B. Riley Wealth Advisors Inc. now owns 17,115 shares of the company’s stock worth $931,000 after acquiring an additional 1,685 shares in the last quarter. Advisory Services Network LLC lifted its position in shares of Sanofi by 7.2% during the first quarter. Advisory Services Network LLC now owns 12,476 shares of the company’s stock valued at $679,000 after buying an additional 838 shares during the last quarter. Rockefeller Capital Management L.P. lifted its position in shares of Sanofi by 2.1% during the first quarter. Rockefeller Capital Management L.P. now owns 178,243 shares of the company’s stock valued at $9,699,000 after buying an additional 3,723 shares during the last quarter. Providence Capital Advisors LLC lifted its position in shares of Sanofi by 3,929.1% during the first quarter. Providence Capital Advisors LLC now owns 2,865,594 shares of the company’s stock valued at $52,657,000 after buying an additional 2,794,472 shares during the last quarter. Finally, Thrivent Financial for Lutherans raised its position in shares of Sanofi by 74.0% in the 1st quarter. Thrivent Financial for Lutherans now owns 17,547 shares of the company’s stock valued at $953,000 after purchasing an additional 7,464 shares during the last quarter. 10.06% of the stock is currently owned by institutional investors.

Sanofi Price Performance

Sanofi stock opened at $54.28 on Thursday. The company’s fifty day moving average price is $53.10 and its 200 day moving average price is $53.63. Sanofi has a 1 year low of $36.91 and a 1 year high of $57.82. The stock has a market capitalization of $137.04 billion, a P/E ratio of 18.61, a P/E/G ratio of 1.58 and a beta of 0.57. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.81 and a current ratio of 1.21.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Friday, July 28th. The company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.07. The company had revenue of $10.85 billion for the quarter, compared to analyst estimates of $11.47 billion. Sanofi had a return on equity of 27.94% and a net margin of 16.07%. As a group, equities research analysts anticipate that Sanofi will post 4.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SNY has been the subject of a number of recent research reports. HSBC initiated coverage on shares of Sanofi in a research report on Friday, July 14th. They set a “buy” rating for the company. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 29th. Finally, Berenberg Bank raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 5th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $72.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.